Increase in R&D Expenses and Investment in Dialysis and Biotechnology
First written in FY2016. 1 of 39 entries say "Advanced", first in 2026-05-12. Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Full-Year R&D Expense UpdateAnnual report
「Research and development expenses for the fiscal year totaled ¥2,013 million, up 17.2% from the same period a year earlier.」
Full-year research and development expenses were ¥2,013 million, up 17.2% year on year. The company cites an increase associated with progress in research and development activities for DMX-200 and other projects as a factor affecting earnings. - FY2026-H1Interim-period research and development expenses updatedAnnual report
「Research and development expenses for the interim accounting period totaled ¥1,225 million.」
Research and development expenses for the interim accounting period were ¥1,225 million, up from ¥714 million in the same period a year earlier. The company also cites an increase associated with progress in research and development activities related to DMX-200. - FY2025Full-Year R&D Expense UpdateAnnual report
「Research and development expenses for the fiscal year totaled ¥1,718 million, up 16.9% from the same period a year earlier.」
Full-year research and development expenses were ¥1,718 million, up 16.9% year on year. The company continues to deepen its focus on infusion and dialysis agents, revitalize dialysis care, and develop new fields. - FY2025-H1Interim-period research and development expenses updatedAnnual report
「Research and development expenses for the interim accounting period totaled ¥714 million.」
Research and development expenses for the interim accounting period were ¥714 million, up from ¥637 million in the same period a year earlier. The company states that there were no significant changes in its research and development activities. - FY2024Full-Year R&D Expense UpdateAnnual report
「Research and development expenses for the fiscal year totaled ¥1,469 million, up 8.5% from the same period a year earlier.」
Full-year research and development expenses were ¥1,469 million, up 8.5% year on year. - FY2024-Q3Updated cumulative R&D expenditure for the third quarterAnnual report
「Research and development expenses for the cumulative third quarter totaled ¥1,050 million.」
Research and development expenses for the cumulative third quarter were ¥1,050 million, up from ¥992 million in the same period a year earlier. - FY2024-Q2Update to first-half R&D expensesAnnual report
「Research and development expenses for the cumulative second quarter totaled ¥637 million.」
Research and development expenses for the cumulative second quarter were ¥637 million, down ¥6 million from ¥643 million in the same period a year earlier. - FY2024-Q1Update to first-quarter R&D expensesAnnual report
「Total R&D expenses for the first quarter cumulative period were ¥328 million.」
Research and development expenses for the cumulative first quarter were ¥328 million, up from ¥321 million in the same period a year earlier. - FY2023Full-Year R&D Expense UpdateAnnual report
「Research and development expenses for the fiscal year totaled ¥1,353 million, down 6.1% from the same period a year earlier.」
Full-year research and development expenses were ¥1,353 million, down 6.1% year on year. The focus of research and development is on revitalizing dialysis care and developing new fields. - FY2023-Q3Updated cumulative R&D expenditure for the third quarterAnnual report
「Total R&D expenses for the third quarter cumulative period were ¥992 million.」
Third-quarter cumulative R&D expenses were ¥992 million, up from ¥922 million in the previous-year period. The company states that there was no material change in the status of R&D activities. - FY2023-Q2Update to first-half R&D expensesAnnual report
「Total R&D expenses for the second quarter cumulative period were ¥643 million.」
Second-quarter cumulative R&D expenses were ¥643 million, up from ¥623 million in the previous-year period. The company states that there was no material change in the status of R&D activities. - FY2023-Q1Update to first-quarter R&D expensesAnnual report
「Total R&D expenses for the first quarter cumulative period were ¥321 million.」
First-quarter cumulative R&D expenses were ¥321 million, down ¥15 million from ¥336 million in the previous-year period. The company states that there was no material change in the status of R&D activities. - FY2022Full-Year R&D Expense UpdateAnnual report
「R&D expenses for the fiscal year totaled ¥1,442 million, a decrease of 1.4% from the previous fiscal year.」
FY2022 full-year R&D expenses were ¥1,442 million, down 1.4% year on year. The policy of revitalizing dialysis care and developing new fields continues. - FY2022-Q3Updated cumulative R&D expenditure for the third quarterAnnual report
「Total R&D expenses for the third quarter cumulative period were ¥922 million.」
Third-quarter cumulative R&D expenses were ¥922 million, down from ¥1,051 million in the previous-year period. The company states that there was no material change in the status of R&D activities. - FY2022-Q2Update to first-half R&D expensesAnnual report
「Total R&D expenses for the second quarter cumulative period were ¥623 million. There was no material change in the status of R&D activities during the second quarter cumulative period.」
FY2022 second-quarter cumulative R&D expenses were ¥623 million, and the company states that there was no material change in the status of R&D activities. - FY2022-Q1Update to first-quarter R&D expensesAnnual report
「Total R&D expenses for the first quarter cumulative period were ¥331 million. There was no material change in the status of R&D activities during the first quarter cumulative period.」
FY2022 first-quarter R&D expenses were ¥331 million, and the company states that there was no material change in the status of R&D activities. - FY2021Full-Year R&D Expense UpdateAnnual report
「R&D expenses for the fiscal year totaled ¥1,462 million, an increase of 3.8% from the previous fiscal year.」
FY2021 full-year R&D expenses were ¥1,462 million, up 3.8% year on year. - FY2021-Q3Updated cumulative R&D expenditure for the third quarterAnnual report
「Total R&D expenses for the third quarter cumulative period were ¥1,066 million.」
Third-quarter cumulative R&D expenses were ¥1,066 million, and the company states that there was no material change in the status of R&D activities. - FY2021-Q2Update to first-half R&D expensesAnnual report
「Total R&D expenses for the second quarter cumulative period were ¥706 million.」
Second-quarter cumulative R&D expenses were ¥706 million, and the company states that there was no material change in the status of R&D activities. - FY2021-Q1Update to first-quarter R&D expensesAnnual report
「Total R&D expenses for the first quarter cumulative period were ¥336 million.」
First-quarter R&D expenses were ¥336 million, up from ¥328 million in the previous-year period. The company states that there was no material change in the status of R&D activities. - FY2020Full-Year R&D Expense UpdateAnnual report
「R&D expenses for the fiscal year totaled ¥1,409 million, a decrease of 20.1% from the previous fiscal year.」
Full-year R&D expenses were ¥1,409 million, down 20.1% year on year. The policy of deepening development of infusion and dialysis products and developing new fields continues separately. - FY2020-Q3Update to R&D expenses for the first 3 quartersAnnual report
「Total R&D expenses for the third quarter cumulative period were ¥1,051 million.」
Third-quarter cumulative R&D expenses were ¥1,051 million, down from ¥1,314 million in the previous-year period. The company states that there was no material change in the status of R&D activities. - FY2020-Q2Update to first-half R&D expensesAnnual report
「Total R&D expenses for the second quarter cumulative period were ¥716 million.」
First-half R&D expenses were ¥716 million, down from ¥877 million in the previous-year period. The company states that there was no material change in the status of R&D activities. - FY2020-Q1Update to first-quarter R&D expensesAnnual report
「Total R&D expenses for the first quarter cumulative period were ¥328 million.」
First-quarter R&D expenses were ¥328 million, and the company states that there was no material change in the status of R&D activities. - FY2019Full-Year R&D Expense UpdateAnnual report
「R&D expenses for the fiscal year totaled ¥1,764 million, a decrease of 12.0% from the previous fiscal year.」
FY2019 full-year R&D expenses were ¥1,764 million, down 12.0% year on year. The company continues to deepen development of its infusion and dialysis products and develop new drug candidates in biotechnology-related fields. - FY2019-Q3Update to R&D expenses for the first 3 quartersAnnual report
「Total R&D expenses for the third quarter cumulative period were ¥1,314 million.」
FY2019 third-quarter cumulative R&D expenses were ¥1,314 million, and the company states that there was no material change in the status of R&D activities. - FY2019-Q2Update to first-half R&D expensesAnnual report
「Total R&D expenses for the second quarter cumulative period were ¥877 million.」
FY2019 second-quarter cumulative R&D expenses were ¥877 million, down from ¥1,081 million in the previous-year period. The company states that there was no material change in the status of R&D activities. - FY2019-Q1Update to first-quarter R&D expensesAnnual report
「Total R&D expenses for the first quarter cumulative period were ¥438 million.」
FY2019 first-quarter R&D expenses were ¥438 million, and the company states that there was no material change in the status of R&D activities. - FY2018Full-Year R&D Expense UpdateAnnual report
「R&D expenses for the fiscal year totaled ¥2,005 million, a decrease of 11.3% from the previous fiscal year.」
FY2018 full-year R&D expenses were ¥2,005 million, down 11.3% year on year. The company continues to deepen development of its infusion and dialysis products and develop new drug candidates in biotechnology-related fields. - FY2018-Q3Update to R&D expenses for the first 3 quartersAnnual report
「Total R&D expenses for the third quarter cumulative period were ¥1,495 million. There was no material change in the status of R&D activities during the third quarter cumulative period.」
R&D expenses for the third quarter cumulative period were ¥1,495 million, and the company states that there was no material change in the status of R&D activities. - FY2018-Q2Update to first-half R&D expensesAnnual report
「Total R&D expenses for the second quarter cumulative period were ¥1,081 million. There was no material change in the status of R&D activities during the second quarter cumulative period.」
R&D expenses for the second quarter cumulative period were ¥1,081 million, and the company states that there was no material change in the status of R&D activities. - FY2018-Q1Update to first-quarter R&D expensesAnnual report
「Total R&D expenses for the first quarter cumulative period were ¥549 million. There was no material change in the status of R&D activities during the first quarter cumulative period.」
FY2018 first-quarter R&D expenses were ¥549 million, and the company states that there was no material change in the status of R&D activities. - FY2017Full-Year R&D Expense UpdateAnnual report
「R&D expenses for the fiscal year totaled ¥2,261 million, an increase of 2.4% from the previous fiscal year.」
FY2017 full-year R&D expenses were ¥2,261 million, up 2.4% year on year. The company is pursuing deeper development of its infusion and dialysis product businesses and the development of new drug candidates in biotechnology-related fields. - FY2017-Q3Updated cumulative R&D expenditure for the third quarterAnnual report
「Total R&D expenses for the third quarter cumulative period were ¥1,616 million. There was no material change in the status of R&D activities during the third quarter cumulative period.」
R&D expenses for the third quarter cumulative period were ¥1,616 million, and the company states that there was no material change in the status of R&D activities. - FY2017-Q2Update to first-half R&D expensesAnnual report
「Total R&D expenses for the second quarter cumulative period were ¥1,092 million. There was no material change in the status of R&D activities during the second quarter cumulative period.」
R&D expenses for the second quarter cumulative period were ¥1,092 million, and the company states that there was no material change in the status of R&D activities. - FY2017-Q1First-Quarter Results AddedAnnual report
「Total R&D expenses for the first quarter cumulative period were ¥619 million.」
The company states that there was no material change in R&D activities, and reported first-quarter R&D expenses of ¥619 million. - FY2016First statedAnnual report
「R&D expenses for the fiscal year totaled ¥2,208 million, an increase of 13.6% from the previous fiscal year.」
R&D expenses were ¥2,208 million, up 13.6% year on year.